Short Selling Commentary

Over the last several months, the Company has posted numerous responses to allegations that have been made against it and its employees. As has been previously discussed, the Audit Committee of our Board of Directors is conducting an independent investigation into current and prior-period matters relating to allegations regarding certain sales and distribution practices at the Company, including allegations made by certain former employees and short sellers. The Company therefore will not continue to post responses to allegations.

We have designated this space on our website to place information that will inform shareholders of the short selling activities in our stock.  We will make posts to this site as necessary.  However, we will not always be in a position to press release the fact that new information has been placed in this area.

MiMedx understands the balance between longs and shorts and the role each plays in our stock market, and MiMedx has absolutely no issues with investors legally short selling stocks. However, illegal short selling must be confronted and stopped. One of the ways short selling turns ILLEGAL is for there to be false data maliciously dropped into the marketplace for the purpose of manipulating a stock's price. It is incumbent upon any publishing author or entity to verify the credibility of their sources and the completeness of the information they receive.


December 13, 2017

For many months, MiMedx has answered on this site all the regulatory related allegations from the illegal short sellers by presenting actual facts and the related regulations and laws. Each time, their allegations have proven to be incorrect. As far as the Company is concerned, these allegations have been created for stock manipulation purposes and are coming from unreliable sources. There is a clear demonstration that these individuals do not understand normal healthcare business and governmental processes and procedures. It is also clear that factual information is not their goal because the allegations are so incorrectly stated.

The previously debunked allegations are beginning to be recycled. Therefore, their new material is no longer very original.

MiMedx will continue to address these allegations even as ridiculous as they are. We are doing this because it is the professional way to approach this matter. Also, this should prove to be extremely helpful in assisting the regulators with their review of all this misinformation and these false allegations. MiMedx would recommend to its shareholders to review the SEC Updated Investor Alert entitled "Social Media and Investing -- Stock Rumors" which is dated November 5, 2015. This publication clearly delineates the goals that illegal short sellers have when they develop their "Pump and Dump" and "Short and Distort" campaigns to manipulate the market.

As this SEC bulletin clearly delineates, these are illegal actions that are taking place in this "Short and Distort" attack against MiMedx. It is our sincere hope that the SEC and other regulatory agencies will understand that these matters are out of control and that they will take some swift and tough action to hold these individuals and institutions accountable. MiMedx will certainly do its best to encourage that action, and we encourage our shareholders to do the same.

December 14, 2017

Mr. Cohodes, you have referred recently to MiMedx ‘Goons’. It would be informative for everyone to know just who you are calling ‘Goons’. Could these be federal regulators?

December 28, 2017

“When someone is making a fool of themselves, do not interrupt”. (author unknown)

These “short sell” tweets and no name publications all have been emotionally driven with no logic, common sense or business acumen behind the comments and allegations. Generally, MiMedx will not respond unless there is an issue that has actual regulatory or legal implications. Much of the commentary consists of old allegations that have been previously refuted on our website. There is no point in responding to meritless business allegations and the demeaning comments about MiMedx personnel.

MiMedx is continuing to cooperate with the SEC in supplying documents and information, and the company expects that the eventual conclusion will be the definitive resolution on these illegal short selling matters. Company executives look forward to setting the records straight on all of the meritless allegations.

Mr. Cohodes,
You have posted on your website and discussed a fraudulent document written by someone who has a short sale thesis on the company. This document is supposedly from a current MiMedx employee and it contains numerous false and ridiculous allegations. The document was sent to numerous newspapers, law firms and several of our competitors. I am asking you to remove this particularly egregious and fraudulent creation from your website and future commentary.

Also, you have never answered our question regarding who were the “MiMedx Goons” you have been referring to in your tweets who came to your home a couple weeks ago. I suggested that if they were federal agents, you should post an apology. Either way, it would be appropriate for you to inform everyone who you were calling “MiMedx Goons”. Thank you.


MiMedx addresses Cohodes Medicare Fraud accusations.
MiMedx Addresses Medicare Comments.
MiMedx Addresses Aurelius.
National Treasury’s views on Viceroy.
MiMedx Addresses Additional Social Media Accusations.
MiMedx Addresses Sunshine Act and PAC donations.
MiMedx Addresses Cohodes and Asks Additional Questions
MiMedx Addresses Cohodes & JP Morgan conference
MiMedx Sales of AmnioFix Injectable
MiMedx Addresses Viceroy 22
MiMedx Addresses Viceroy 21
MiMedx Addresses Viceroy 20
MiMedx Addresses Sunshine Act
MiMedx Addresses Viceroy 19 and Related Tweet
Letter to Shareholders
MiMedx provides further information
MiMedx addresses Viceroy
MiMedx addresses Village Podiatry
MiMedx addresses Viceroy
MiMedx views the final HCT/P Guidance document as generally beneficial to the Company, physicians and patients.
Cohodes now thinks he’s an expert in FDA regulations. Please read and review the following white paper which we published over 2 years ago. It should clarify what can be very complex issues.

MiMedx Addresses Lopez Article

MiMedx addresses additional false information.
MiMedx addresses adverse event posts on social media.
MiMedx addresses legal excerpts on social media.
MiMedx addresses Twitter personas.
MiMedx addresses Cohodes lies.
MiMedx discusses Osiris.
MiMedx addresses Viceroy Reports.
Letter from Mr. Petit of MiMedx to Marc Cohodes.
MiMedx addresses Viceroy.
MiMedx exposes this short seller’s website dedicated to posting FALSE and Defamatory information about MiMedx and encourages all readers to view this alert from the SEC that warns investors about fraudsters who may attempt to manipulate share prices by using social media to spread false or misleading information about stocks:
MiMedx addresses Viceroy.
MiMedx addresses Citron Research.
MiMedx addresses recent Tweet.
MiMedx addresses First Analysis Report.
This MiMedx document address the Viceroy report with the catchy title.
MiMedx addresses additional false and misleading information.
This document from Mr. Petit addresses difficult personalities.
This MiMedx press release warns of suspicious emails impersonating company officers.
This MiMedx document exposes the false and misleading information distributed most recently.
This document from Mr. Petit addresses the latest short story regarding MiMedx.
This MiMedx document exposes the false and misleading information distributed by Viceroy Research and Aurelius Value.
MiMedx response to false and misleading information regarding call recordings

Legal Activities

A copy of the lawsuit filed in the US District of Court for the Southern District of New York is posted.
A copy of the lawsuit filed in the US District of Court for the District of Columbia is posted.


This is an Anonymous Article
This Article written by Jonathan Shapiro, Vesna Poljak and Tony Boyd was published January 18, 2018, 6:14 pm on Financial Review is available on the Financial Review website.
This article, by Edward Knight, Opinion Contributor, was published by The Hill on 01/15/18 04:00 pm EST
This article, written by Trent Walsh was published by Seeking Alpha on January 3, 2018.
This article, written by Derek J. Bell, Partner and Katelyn Ellins, Associate of DLA Piper in Canada addresses short selling and company responses to short-sellers.
This Counterfeiting Stock article explains in everyday terms what short selling, illegal naked short selling, and other stock manipulations are, and how they affect companies and investors.  Further, it details the 'Anatomy of a Short Attack', and explains 'who' and 'how' participants make money through illegally shorting a stock. This article is published by Citizens for Securities Reform on their website (
This article highlights issues related to naked short selling.